RP3 not checked

Replimune, Inc.

FollowEvery change as it happens, and a Monday email
Stage
 
Next date
Phase 1 trial completes
Trials
1 active
3 in total · 1 in the EU
Targets
 

What this is

How it works
How it works isn't classified yet
Tested for
Advanced Solid Tumor
Main trialPhase 1
“This is a Phase 1, multicenter, open label, single agent dose escalation and combination treatment study of RP3 in adult participants with advanced solid tumors, to evaluate the safety and tolerability of RP3 both as a single agent and in combination with anti-PD1 therapy and to determine the recommended Phase 2 dose (RP2D) of RP3.”In the company’s words, NCT04735978 on ClinicalTrials.gov

Other drugs for Advanced Solid Tumor

All 2440 drugs for Advanced Solid Tumor

Coming up1

Changes0

Last 90 days

No changes yet. We started recording changes on 6 Nov 2026.

Trials3

TrialPhaseCompletesWhat it tests
Phase 1Active, not recruiting 30 Nov 2026 Study of RP3 Monotherapy and RP3 in Combination With Nivolumab in Patients With Solid Tumours
Phase 2Terminated 18 Aug 2025 RP2/RP3 in Combination With Atezolizumab and Bevacizumab for the Treatment of Patients With CRC
Phase 2Withdrawn 1 Mar 2026 Study of RP3 in Combination With Nivolumab and Other Therapy in Patients With Locoregionally Advanced or Recurrent SCCHN
A trial in both registries shows both numbers.

About

Sources
ClinicalTrials.gov updated 18 Nov 2026 · EU trials register (CTIS) updated 18 Nov 2026 · openFDA updated 17 Nov 2026

Follow RP3

Following is part of Solo: you see every change to RP3 the day it happens.

Solo

$49a month, excl. VAT

  • Follow up to 5 landscapes, companies or drugs
  • Every change, the day it happens
  • A Monday email with the week’s changes
Choose Solo

Free

$0no card

  • One landscape of your own, in full
  • The top 10 of everything else
Sign up free

Have an account? Sign in